A recent Gastroenterology digest,
as sent to subscribers

Study Type: Economic modelling study using GLOBOCAN registry data (cross-national, 185 countries, 2022).

Key Question: What is the global economic burden of GI cancer mortality in working-age adults when unpaid work is valued alongside paid labour?

Key Findings:

• GI cancers caused 1.16 million working-age deaths in 2022, with estimated productivity losses of $177.81 billion (31.4% of all cancer-related losses).
• Losses were highest for liver ($50.45 billion; 28.4%) and colorectal cancer ($49.53 billion; 27.9%); unpaid work accounted for 42.19% of the total.
• Unpaid work comprised 59% of female losses versus 35% of male losses; very-high HDI countries had the largest absolute loss ($92.13 billion).

Clinical Relevance: Standard cost-effectiveness frameworks may undervalue GI cancer prevention and early detection (e.g., bowel screening) by omitting unpaid work, particularly in women, which is relevant to UK commissioning and health-economic appraisals.

Limitations: Estimates rely on modelled GLOBOCAN data, human capital and opportunity cost assumptions, and country-level wage and time-use inputs, so UK-specific figures are not reported and uncertainty ranges are not given in the abstract.

Study Type: Narrative review and expert consensus statement (US Multi-Society Task Force); no original data or systematic methodology described in the abstract.

Key Question: How should serrated polyposis syndrome (SPS) be recognised, managed and surveilled, and what should be offered to affected families?

Key Findings:

• Diagnosis relies on WHO clinical criteria (polyp size, cumulative number, location); SPS is under-recognised despite being the commonest polyposis syndrome, and carries increased prevalent and incident CRC risk.
• Management comprises meticulous inspection, colonic clearance and frequent surveillance colonoscopy; surgery is reserved for CRC or polyp burden unmanageable endoscopically by expert endoscopists.
• No common germline variant is associated with SPS; genetic testing is indicated only where criteria for a known hereditary syndrome are met. First-degree relatives should have colonoscopic screening.

Clinical Relevance: Supports identifying SPS in BCSP and surveillance cohorts and offering colonoscopic screening to first-degree relatives, though UK practice follows BSG/ACPGBI/UKCGG guidance, so recommendations should be cross-checked against local pathways.

Limitations: The abstract gives no quantitative risk estimates, surveillance intervals or evidence grading, so recommendation strength cannot be judged.

Study Type: Preclinical experimental study (mouse model; Piebald lethal sl/sl).

Key Question: Can diet modify gut microbial composition and epithelial physiology to improve survival in a Hirschsprung disease (HSCR) model prone to enterocolitis?

Key Findings:

• A protective diet tripled median sl/sl lifespan, with colonic epithelial hypoxia, preserved mitochondrial metabolism, improved barrier function (FITC-dextran), increased proximal antimicrobial peptides and reduced Enterobacteriaceae. The detrimental diet produced the opposite picture (raised epithelial oxygen, abnormal mitochondria, Enterobacteriaceae expansion).
• Protective diet-fed mice had higher faecal butyrate, a candidate mediator, though causality was not established.
• Tungstate, which inhibits Enterobacteriaceae anaerobic respiration, also improved survival, supporting a causal role for these bacteria.

Clinical Relevance: This suggests a possible dietary or microbiome-targeted approach to HSCR-associated enterocolitis, which remains a major cause of morbidity and mortality in paediatric surgical practice, though it is hypothesis-generating only.

Limitations: Findings come from a single mouse model with no human data, so translation to HSCR patients and to feasible dietary interventions is unproven.

Study Type: Narrative review (global epidemiology update). The abstract does not describe a systematic search or formal synthesis methodology.

Key Question: What is the current global burden of liver disease by aetiology and region, and what priorities would reduce it?

Key Findings:

• CLD affects over 1.5 billion people; cirrhosis is the 12th leading cause of death, and cirrhosis plus primary liver cancer cause nearly 2.4 million deaths annually, disproportionately in low- and middle-income countries.
• ALD and MASLD are expected to drive rising burden (obesity, demographic change, alcohol use), while vaccination and antivirals continue to reshape viral hepatitis epidemiology.
• Africa now has the highest age-standardised mortality from cirrhosis and liver cancer (viral hepatitis, aflatoxin, limited care access); liver transplantation is available to only a minority globally.

Clinical Relevance: The projected rise in ALD and MASLD, and their increasing overlap, supports UK investment in early fibrosis detection, alcohol and metabolic interventions, and continued progress towards viral hepatitis elimination.

Limitations: The abstract gives no UK or Europe-specific data, and as a narrative review it lacks stated methods for evidence selection, so potential selection bias cannot be assessed.

Study Type: Expert consensus statement and narrative review (US Multi-Society Task Force). The abstract does not specify methodology, such as a systematic search or formal grading of evidence.

Key Question: How should serrated polyposis syndrome (SPS) be recognised, managed and followed up, including the approach to genetic testing and relatives?

Key Findings:

• SPS is the most common polyposis syndrome but is frequently unrecognised. Diagnosis rests on WHO criteria (polyp size, cumulative lifetime number, location).
• SPS carries increased prevalent and incident CRC risk. Recommended management is meticulous endoscopic clearance with frequent surveillance; surgery is reserved for CRC or polyp burden not endoscopically manageable by expert endoscopists.
• No common germline pathogenic variant exists, so genetic testing is indicated only if criteria for another hereditary syndrome are met. First-degree relatives should undergo colonoscopic screening.

Clinical Relevance: Supports case-finding and surveillance of SPS in UK practice, though US recommendations should be reconciled with BSG/ACPGBI/PHE guidance on surveillance intervals and relative screening.

Limitations: The abstract gives no quantitative risk estimates, surveillance intervals or evidence grading, so recommendation strength cannot be assessed.

Study Type: Multinational prospective observational cohort study with machine learning prognostic modelling (n=679 outpatients, seven countries).

Key Question: Does stool metagenomic profiling add prognostic value beyond clinical variables for predicting 90-day non-elective hospitalisation in outpatients with cirrhosis?

Key Findings:

• 25% of patients were hospitalised within 90 days. These patients had more advanced disease and lower microbial diversity, consistent across countries. Nineteen species remained independently associated after adjustment, including enrichment of *Enterococcus faecium* and *Veillonella rogosae* and depletion of commensal taxa, with loss of short-chain fatty acid-producing taxa.
• Functional and antibiotic resistance gene alterations were also associated with hospitalisation.
• The combined model (AUC 0.84) outperformed clinical-only (0.79) and microbiome-only (0.74) models.

Clinical Relevance: Microbiome profiling may eventually refine risk stratification for hospitalisation in cirrhosis, though it is not yet a practical tool for NHS clinics.

Limitations: The abstract does not report external validation, and the modest AUC gain (0.79 to 0.84) needs confirmation before clinical utility can be assumed.

Study Type: Nationwide registry-based retrospective cohort study (Netherlands, 2008–2018).

Key Question: What proportion of patients treated for Barrett-related dysplasia or oesophageal adenocarcinoma had prior endoscopic surveillance?

Key Findings:

• Of 8914 treated patients, 90% (95% CI 89–91%) presented de novo without prior endoscopy; only 10% (889) had at least one prior endoscopy showing non-dysplastic BE.
• Advanced disease (stage ≥II) was far commoner in de novo patients (70% vs 11% with prior endoscopy; p<0.001).
• Even among endoscopically treated patients, 65% (1283/1989) presented de novo; missed advanced neoplasia in the surveilled group was low (11%; 96/889).

Clinical Relevance: Surveillance of known BE reaches only a small minority of those who develop dysplasia or EAC, supporting debate in the UK on targeted screening strategies (e.g. Cytosponge-based pathways) alongside existing surveillance.

Limitations: Prior endoscopy status was inferred from pathology reports, so undocumented or non-histology-recorded endoscopies may have been misclassified, and the data cannot show whether surveillance improved outcomes.

Study Type: Multi-omics observational cohort study (n=156) with preclinical mouse model validation.

Key Question: What are the molecular features of steatohepatitic HCC (SH-HCC), and can they support non-invasive diagnosis and identify therapeutic targets?

Key Findings:

• A 12-species lipid panel distinguished SH-HCC from conventional HCC in an independent cohort (AUC 0.909); a serum proteomic model performed less well (AUC 0.828, test cohort).
• Spatial transcriptomics showed greater immune infiltration but a reinforced immune barrier and reduced tumour-immune communication. Drug response modelling predicted reduced sorafenib and immunotherapy responsiveness, with TACE possibly remaining effective.
• In Sleeping Beauty mouse models, FABP4 deletion suppressed tumour growth, remodelled the immune microenvironment and enhanced anti-PD-1 response.

Clinical Relevance: With MASLD-related HCC rising in the UK, a non-invasive means of identifying SH-HCC could inform treatment selection, particularly given the signal of reduced immunotherapy benefit.

Limitations: Small sample sizes for several omics layers (e.g. spatial metabolomics n=6), and treatment-response conclusions rest on in silico drug-response analysis and mouse data, not clinical outcomes.